Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase EARLY_PHASE1 1Phase 1 1

Status

Active not recruiting 3Unknown 1Recruiting 1

Sponsor Class

OTHER 5NIH 2NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 5

Conditions

Breast Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 2Inflammatory Breast Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × OTHER × 2C4 antibody × Clear all
NCT04329065 2026-05-19

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

University of Washington

Phase 2 Recruiting
25 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT07407920 2026-02-12

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
Breast

Anatomic Stage I Breast Cancer AJCC v8

NCT02827877 2025-11-14

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
18 enrolled 8 charts
Breast

Breast Neoplasms

NCT01730833 2025-06-03

Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
63 enrolled 11 charts
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT04197687 2023-12-18

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Academic and Community Cancer Research United

Phase 2 Unknown
480 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡